Updates from the Society for Neuro-Oncology Annual Meeting

Last week, we attended the world's largest brain tumor science fair: the Society for Neuro-Oncology (SNO) Annual Meeting in Miami. 

There were a number of newsworthy presentations, including encouraging clinical trial updates about Tocagen's novel gene therapy and Celldex Therapeautics' investigational immunotherapy.  ABC2 has been an early funder and collaborator in both of these efforts. 

Al Musella, Musella Foundation

Novocure's presentation at SNO resulted in an article by the New York Times about Novocure's novel scalp device that zaps tumors with electrical current.  While we have not funded Novocure's therapy, our friend and colleague, Al Musella, founder of the Musella Foundation, has been an early champion of the Novocure treatment.  Al recently wrote a thought-provoking blog post about the potential impact Novocure's device could have on treating brain tumors in the future.


Share |
February 13, 2022 12:09 PM
He plans to build another world-class brain tumor center and our team at ABC2 looks forward to working with him.
February 10, 2022 12:24 PM
ABC2 is funding the whole exome sequencing of NeoVax tumors at the Broad Institute to assist Dana-Farber researchers.

Join us in our fight for a cure!